Last reviewed · How we verify
Saw palmetto and sanmiaoshan capsule
Saw palmetto and sanmiaoshan capsule is a Small molecule drug developed by Hospital Authority, Hong Kong. It is currently in Phase 1 development.
At a glance
| Generic name | Saw palmetto and sanmiaoshan capsule |
|---|---|
| Sponsor | Hospital Authority, Hong Kong |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saw palmetto and sanmiaoshan capsule CI brief — competitive landscape report
- Saw palmetto and sanmiaoshan capsule updates RSS · CI watch RSS
- Hospital Authority, Hong Kong portfolio CI
Frequently asked questions about Saw palmetto and sanmiaoshan capsule
What is Saw palmetto and sanmiaoshan capsule?
Saw palmetto and sanmiaoshan capsule is a Small molecule drug developed by Hospital Authority, Hong Kong.
Who makes Saw palmetto and sanmiaoshan capsule?
Saw palmetto and sanmiaoshan capsule is developed by Hospital Authority, Hong Kong (see full Hospital Authority, Hong Kong pipeline at /company/hospital-authority-hong-kong).
What development phase is Saw palmetto and sanmiaoshan capsule in?
Saw palmetto and sanmiaoshan capsule is in Phase 1.